KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) (NCT07252739)
KEYMAKER-U01 Substudy 01J: A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations
🩺 Plain-English Summary (8th-Grade Level)
Researchers want to learn if using a study medicine called MK-1084 can help treat Non-Small Cell Lung Cancer (NSCLC). MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this study is to learn about the safety of MK-1084 and to learn how many people have the cancer get smaller or go away during the study treatment.
Who can join: Review the eligibility criteria below.
Location: Clermont Oncology Center ( Site 0041) — Clermont, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (38 Sites)
Showing the first 25 of 38 sites.
- Clermont Oncology Center ( Site 0041) — Clermont, Florida
- Sanford Health Roger Maris Cancer Center ( Site 0039) — Fargo, North Dakota
- Sanford Cancer Center Oncology Clinic ( Site 0038) — Sioux Falls, South Dakota
- Fundacion Arturo Lopez Perez ( Site 0167) — Santiago, Region M. de Santiago
- Centro de Oncología de Precisión ( Site 0160) — Santiago, Region M. de Santiago
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 0318) — Nanjing, Jiangsu
- The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 0306) — Nanchang, Jiangxi
- Zhongshan Hospital Fudan University ( Site 0319) — Shanghai, Shanghai Municipality
- West China Hospital, Sichuan University ( Site 0315) — Chengdu, Sichuan
- Kuopion Yliopistollinen Sairaala ( Site 0261) — Kuopio, Northern Savonia
- Vaasan Keskussairaala ( Site 0263) — Vaasa, Pohjanmaa
- Turku University Hospital ( Site 0262) — Turku, Southwest Finland
- HYKS Syöpätautien klinikka ( Site 0260) — Helsinki, Uusimaa
- Evangelismos General Hospital of Athens ( Site 0200) — Athens, Attica
- Hong Kong Integrated Oncology Centre ( Site 0232) — Central,
- Hong Kong United Oncology Centre ( Site 0231) — Kowloon,
- Queen Mary Hospital ( Site 0230) — Pokfulam,
- Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0175) — Milan, Lombardy
- Deventer Ziekenhuis ( Site 0272) — Deventer, Overijssel
- Leids Universitair Medisch Centrum ( Site 0273) — Leiden, South Holland
- Severance Hospital Yonsei University Health System ( Site 0080) — Seoul,
- Hospital Universitario Virgen de la Macarena ( Site 0093) — Seville,
- Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 0351) — Bangkok, Bangkok
- Faculty of Medicine Siriraj Hospital ( Site 0350) — Bangkok, Bangkok
- Erciyes University ( Site 0145) — Talas, Kayseri
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Malignant Neoplasm
- Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment — Duarte, California
- Reproductive Health Program in Patients With Cancer — Jonesboro, Arkansas
- rTMS in Improving Neuropathy in Patients With Stage I-IV Cancer Who Have Received Oxaliplatin Chemotherapy — Houston, Texas
- Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer — Newark, Delaware
- Web-Based Family Outreach Program for Cancer Prevention in High-Risk Families — Houston, Texas
- Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies — Los Angeles, California
Explore by condition: All Malignant Neoplasm clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.